Clinical trialsCompany release

Lexeo reports interim LX2020 data in PKP2 cardiomyopathy, cites FDA openness to NSVT endpoint

🇺🇸 Lexeo Therapeutics, Inc. (LXEO) · Mon 16 Nov 2026

Interim results for the gene therapy show falls in arrhythmia measures, and the company says FDA is open to a surrogate endpoint for accelerated approval.

Lexeo Therapeutics has reported interim data for its gene therapy LX2020 in arrhythmogenic cardiomyopathy linked to PKP2 mutations. The figures come from the company's investor presentation, dated 16 November 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Lexeo Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Lexeo Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →